Top 50 Biotech Innovators: LY Biotech Secures Nearly RMB 100 Million Series A; Xigene Therapeutics Raises Over RMB 70 Million in Pre-A Funding
Signet Therapeutics
Developer of Innovative Targeted Cancer Therapies
1
Shenzhen Renying Biotechnology Co., Ltd. Completes Nearly 100 Million Yuan in Series A Financing
2
SIGNETRaised over 70 million yuan in Pre-A funding and project grants
PART.1
Shenzhen Renying Biotechnology Co., Ltd.
Recently,Top 50 Biotech Innovation Enterprises of the 7th Edition – Rising Star Enterprise: Shenzhen Renying Biotechnology Co., Ltd. (hereinafter referred to as“Shenzhen Renying Biotechnology Co., Ltd.”）Announced the completion of nearly 100 million yuan in Series A financing.
Shenzhen Renying Biotechnology Co., Ltd. is a synthetic biology enterprise that provides high-quality and efficient R&D services and protein raw materials for different application scenarios of proteins, based on structural biology and cutting-edge artificial intelligence computing, and specializes in protein design and modification.
PART.2
SIGNET
Top 50 Biotech Innovation Enterprises of the 7th Edition – Signet Therapeutics (Shenzhen) Co., Ltd. ("Signet Therapeutics" for short) recently announced that the company has secured over 70 million RMB in Pre-A round financing and project funding.This round of financing will be used to support the Phase I clinical trial of the first pipeline, SIGX1094, and to accelerate the IND application process for the second pipeline. In addition, the company will further optimize and upgrade its organoid disease model platform to empower a broader range of new drug development needs.
SIGNET is the first company in China to develop innovative targeted cancer drugs based on organoid disease models + AI. The company currently has four drug pipelines, with the first pipeline developing SIGX1094, the world's first targeted drug for diffuse gastric cancer. It has successively obtained IND approval from the U.S. FDA and China NMPA, and received orphan drug designation from the U.S. FDA. It has now entered Phase I clinical trials.
About the Top 50 Selection of Biotechnology Innovation
The Top 50 Biotech Innovation Enterprises in the Guangdong-Hong Kong-Macao Greater Bay Area, hosted by the Zhongchuang Industry Research Institute and organized by Guangdong Medical Valley, has successfully been held for seven consecutive sessions. As the largest and most dynamic multilateral resource exchange and sharing industrial innovation ecosystem in the Greater Bay Area's biopharmaceuticals industry, it aims to discover China’s future biotech unicorns. The initiative provides a platform for resource integration among enterprises, academia, and government, promoting the development of China’s biopharmaceuticals industry through industrial collaboration and resource aggregation.
